Compound News and Research

RSS

Novel therapeutic approach to treat leukaemia patients

Cancer cells have an abnormal cell division and survival machinery - they grow faster than they die. For their permanent development, they produce an excess of growth factors and nutrients and block the body's own safety mechanisms.

17 May 2016

Magic mushroom compound may offer potential new way for antidepressant research

Psilocybin – a hallucinogenic compound derived from magic mushrooms – may offer a possible new avenue for antidepressant research, according to a new study published in The Lancet Psychiatry today.

17 May 2016

Arkin Holdings and Primera Capital lead investment of $13M in BioSight

BioSight, Ltd, an Israeli pharmaceutical development company focused on the development of innovative chemotherapy pro-drugs with reduced toxicity, announced today the closing of an investment of $13M led by the Mori Arkin's pharmaceutical investment firm, Arkin Holdings, and the US based venture firm Primera Capital. Proceeds of the financing will be used to fund a multi-center phase IIb clinical trial with the company's lead product, Astarabine™, for the treatment of AML.

16 May 2016

Simple, cheap chemical sensors may detect developing cancers in future

Many cancers could be successfully treated if the patient consulted the doctor sufficiently early. But how can a developing cancer be detected if it doesn't give rise to any symptoms? In the near future, suitably early diagnosis could be provided by simple and cheap chemical sensors - thanks to special recognizing polymer films developed at the Institute of Physical Chemistry of the Polish Academy of Sciences in Warsaw.

12 May 2016

High-throughput screening can help detect multiple compounds with potent antimicrobial activity

A new study in which researchers rapidly screened more than 11,000 bioactive molecules for activity against an antibiotic-resistant strain of Klebsiella pneumoniae bacteria identified multiple compounds with potent antimicrobial activity.

12 May 2016

Combination of two compounds found in red grapes, oranges could treat diseases

A combination of two compounds found in red grapes and oranges could be used to improve the health of people with diabetes, and reduce cases of obesity and heart disease.

12 May 2016

Thermo Fisher Scientific reinforces ongoing commitment to make advanced technologies more accessible to customers

Thermo Fisher Scientific Inc., the world leader in serving science, today reinforced its ongoing commitment to help its customers accelerate innovation and enhance productivity.

12 May 2016

Comprehensive genomic characterizations of ACC provide potentially better treatment options

An international team of scientists, including those at the Translational Genomic Research Institute (TGen), have discovered new avenues of potential treatments for a rare and deadly cancer known as Adrenocortical Carcinoma, or ACC.

11 May 2016

Mathematical modeling could lead to better ways of testing cosmetic, consumer products

Researchers at the University of Cincinnati James L. Winkle College of Pharmacy are presenting collaborative research on the use of mathematical methods for understanding the transportation of chemical compounds in biological tissues, like the skin.

11 May 2016

Digital health: putting patients at the center. An interview with Roz Davies

In England alone the NHS sees 1 million patients every 36 hours and there are 3 million volunteers across health and social care many of whom are motivated by their personal experience of healthcare services.

10 May 2016

TSRI scientists design potential drug candidate to treat triple negative breast cancer

In a development that could lead to a new generation of drugs to precisely treat a range of diseases, scientists from the Florida campus of The Scripps Research Institute have for the first time designed a drug candidate that decreases the growth of tumor cells in animal models in one of the hardest to treat cancers—triple negative breast cancer.

10 May 2016

Minihepcidins may potentially treat serious genetic blood diseases in children, adults

New research suggests that synthetic peptides called minihepcidins may potentially treat two serious genetic blood diseases in children and adults. Although those diseases, beta-thalassemia and polycythemia vera, have opposite effects on red blood cell production, treating animals with minihepcidin helps to restore normal levels of red blood cells and reduces spleen enlargement. It also controls the accumulation of excess levels of iron in beta-thalassemia that often causes severe toxic effects.

9 May 2016

Physicians come together for single-payer national health insurance reform

In a dramatic show of physician support for deeper health reform - and for making a decisive break with the private insurance model of financing medical care - 2,231 physicians called today [Thursday, May 5] for the creation of a publicly financed, single-payer national health program that would cover all Americans for all medically necessary care.

6 May 2016

Leica Microsystems launches IOLcompass Pro intraocular lens positioning system

Leica Microsystems in partnership with TrueVision Systems Inc. launches the IOLcompass Pro. IOLcompass Pro is a software-based guidance system for pre-operative planning and intra-operative positioning of premium intraocular lenses (IOLs). It supports ophthalmic surgeons to achieve minimal residual astigmatism for their patients by providing stable and accurate guidance throughout the cataract surgical workflow.

From Leica Microsystems GmbH 5 May 2016

Use of cosmetics during pregnancy can have adverse effects on newborn’s health

A study led by SUNY Downstate Medical Center's School of Public Health presents evidence linking personal care products used during pregnancy to adverse reproductive effects in newborns.

5 May 2016

IONICON exhibits new PTR-TOF 1000 ultra trace gas analyzer at Analytica 2016

The PTR-TOF 1000 ultra is the new benchmark for ultra-sensitive volatile organic compound (VOC) analysis in real-time. Integrated in an affordable, small and light PTR-TOFMS instrument.

From Ionicon Analytik Ges.m.b.H. 5 May 2016

Bayer-new phase 3 liver cancer data

Bayer has announced that a Phase III trial evaluating its oncology compound Stivarga® (regorafenib) tablets for the treatment of patients with unresectable hepatocellular carcinoma (HCC) has met its primary endpoint of a statistically significant improvement in overall survival. The study, called RESORCE, evaluated the efficacy and safety of regorafenib in patients with HCC whose disease has progressed after treatment with sorafenib. The safety and tolerability were generally consistent with the known profile of regorafenib. Detailed efficacy and safety analyses from this study are expected to be presented at an upcoming scientific congress.

4 May 2016

Long-term use of herbal remedies may not guarantee safety

Millions of people around the world use herbal health remedies, following a tradition that began millennia ago. Many believe that herbs are safe because they have been used for many years, but researchers from Baylor College of Medicine and Stony Brook University are raising awareness that long-term use of herbal remedies is no guarantee of their safety. The invited commentary appears in EMBO reports.

4 May 2016

Controlling cholesterol metabolism could help reduce pancreatic cancer spread

Researchers have shown how controlling cholesterol metabolism in pancreatic cancer cells reduces metastasis, pointing to a potential new treatment using drugs previously developed for atherosclerosis.

4 May 2016

New investigational inhibitor JQEZ5 can block specific molecular malfunctions driving cancer

In a step forward in the push for targeted treatments that can block the specific molecular malfunctions driving cancer, University of North Carolina Lineberger Comprehensive Cancer Center researchers have demonstrated how a genetic mutation can drive the most common type of lymphoma as well as melanoma, the deadliest form of skin cancer.

3 May 2016